HC Wainwright Forecasts Weaker Earnings for BridgeBio Pharma

Posted by George Bondi on Sep 4th, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) – HC Wainwright cut their Q3 2026 EPS estimates for BridgeBio Pharma in a research report issued on Wednesday, September 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.40) per share for the quarter, down from their prior estimate of ($0.38). HC Wainwright has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q4 2026 earnings at $0.13 EPS, FY2026 earnings at ($1.88) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at $0.19 EPS, Q3 2027 earnings at $0.49 EPS, Q4 2027 earnings at $0.79 EPS and FY2027 earnings at $1.31 EPS.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The business had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. The business’s quarterly revenue was up 120.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) earnings per share.

A number of other analysts have also recently commented on the stock. Citigroup upped their price objective on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Truist Financial boosted their target price on BridgeBio Pharma from $102.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Mizuho increased their price target on BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday. Wells Fargo & Company increased their price target on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Finally, UBS Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Wednesday. Twenty research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.53.

Get Our Latest Report on BBIO

BridgeBio Pharma Stock Down 1.4%

Shares of NASDAQ BBIO opened at $75.41 on Friday. BridgeBio Pharma has a twelve month low of $48.78 and a twelve month high of $93.42. The stock has a market cap of $14.74 billion, a price-to-earnings ratio of -21.12 and a beta of 0.97. The company’s fifty day moving average is $80.65 and its 200-day moving average is $73.61.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently modified their holdings of the company. Silvant Capital Management LLC bought a new position in shares of BridgeBio Pharma during the second quarter worth about $28,000. Allworth Financial LP acquired a new stake in BridgeBio Pharma in the 2nd quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd bought a new stake in BridgeBio Pharma in the 3rd quarter valued at approximately $34,000. Jones Financial Companies Lllp bought a new stake in BridgeBio Pharma in the 1st quarter valued at approximately $35,000. Finally, Farther Finance Advisors LLC boosted its position in BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after acquiring an additional 245 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

Insider Activity at BridgeBio Pharma

In related news, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the transaction, the chief accounting officer directly owned 127,401 shares of the company’s stock, valued at approximately $10,199,724.06. This represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 148,589 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the completion of the transaction, the director directly owned 8,383 shares of the company’s stock, valued at approximately $742,230.82. The trade was a 94.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 347,343 shares of company stock valued at $27,591,000 over the last three months. Insiders own 14.23% of the company’s stock.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target. Barclays and Cantor Fitzgerald also maintained Buy ratings, supporting the bullish view that BridgeBio’s pipeline could drive substantial long-term value. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma Barclays Sticks to Its Buy Rating for BridgeBio Pharma
Positive Sentiment: BridgeBio will present new PROPEL 3 data on oral infigratinib’s impact on medical complications in children with achondroplasia at the ESPE 2026 meeting on September 9. Additional presentations will cover longer-term efficacy and safety, infant and toddler studies, and hypochondroplasia. The data could provide an important catalyst for the company’s skeletal-dysplasia program. BridgeBio to Present New Data on Oral Infigratinib
Neutral Sentiment: The upcoming infigratinib presentations are potentially significant, but the announcement did not include the actual clinical results. Because the drug remains investigational, investors will likely wait for the September 9 data before assigning greater value to the program.
Negative Sentiment: HC Wainwright lowered EPS estimates across nearly every reported period: Q3 2026 to a loss of $0.40 from $0.38, FY2026 to a loss of $1.88 from $1.50, Q1 2027 to a loss of $0.18 from $0.11, and FY2027 to $1.31 from $2.19. Estimates for Q2, Q3 and Q4 2027 were also reduced. The cuts suggest a slower earnings ramp and are likely the main reason the news is pressuring BBIO, despite the unchanged Buy rating and $120 target.
Negative Sentiment: BridgeBio remains expected to report a full-year loss of approximately $2.60 per share, reinforcing concerns about near-term profitability. Reported insider activity also shows extensive selling and no purchases during the past six months, which may add to investor caution.

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.